Latest Intelligence on Biotechnology

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

HGS: good news for genomics companies

Published By Datamonitor
14 Sep 2000
Expert View
Expert View

The monoclonal model of drug development

Published By Datamonitor
15 Sep 2000
CommentWire
CommentWire

Eli Lilly: cheeky but risky insulin strategy

Published By Datamonitor
19 Sep 2000
CommentWire
CommentWire

Antisoma: rollercoaster ride

Published By Datamonitor
19 Sep 2000
Expert View
Expert View

Waste not, want not: drug delivery to the rescue

Published By Datamonitor
22 Sep 2000
CommentWire
CommentWire

Cell Pathways: FDA rejection could spell trouble

Published By Datamonitor
25 Sep 2000
CommentWire
CommentWire

Scotia: Foscan falters at the final hurdle

Published By Datamonitor
27 Sep 2000
CommentWire
CommentWire

Serono: fertile market for Ovidrel

Published By Datamonitor
03 Oct 2000
CommentWire
CommentWire

Alza: a new focus on in-house development

Published By Datamonitor
06 Oct 2000
Expert View
Expert View

From pens to transplants: what next for insulin?

Published By Datamonitor
06 Oct 2000

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.